Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT04440592 is registered in ClinicalTrials.gov with Tanabe Pharma America, Inc. as lead sponsor.

NCT NCT04440592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04440592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Lead sponsor
Tanabe Pharma America, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 5, 2021
Completion date
February 14, 2024
Enrollment
76 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis